1. Catalog
  2. Nodes
  3. path(MESH:"Diabetes Mellitus, Type 2")

path(MESH:"Diabetes Mellitus, Type 2")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
Diabetes Mellitus, Type 2
Namespace
mesh
Namespace Version
20180828
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh-names.belns

Appears in Networks 3

Nuclear receptors as therapeutic targets for Alzheimer's disease. v1.0.0

Tau Modifications v1.9.5

Tau Modifications Sections of NESTOR

Activation and regulation of the inflammasomes v1.0.0

In-Edges 4

a(CHEBI:pioglitazone) decreases path(MESH:"Diabetes Mellitus, Type 2") View Subject | View Object

The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(CHEBI:rosiglitazone) decreases path(MESH:"Diabetes Mellitus, Type 2") View Subject | View Object

The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes. PubMed:21718217

Appears in Networks:
Annotations
Confidence
High

a(HBP:"O-GlcNAcylation") negativeCorrelation path(MESH:"Diabetes Mellitus, Type 2") View Subject | View Object

This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies. PubMed:19732809

Appears in Networks:

path(MESH:"Immune System Diseases") increases path(MESH:"Diabetes Mellitus, Type 2") View Subject | View Object

At the same time, we have learnt that immune dysregulation contributes to prevalent diseases in Western societies such as atherosclerosis, type 2 diabetes, cancer and neurodegenerative diseases. PubMed:23702978

Appears in Networks:
Annotations
Confidence
High

Out-Edges 1

path(MESH:"Diabetes Mellitus, Type 2") negativeCorrelation a(HBP:"O-GlcNAcylation") View Subject | View Object

This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose. From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies. PubMed:19732809

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.